Search research articles
Contact Us
Filters
Showing results (81-90 of 91) with videos related to
Page
of 10
Sort By:
Journal of Gastroenterology and Hepatology
|
January 19, 2016
Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naïve patients in China and South Korea
Lai Wei, Tao Han, Dongliang Yang, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society
|
March 16, 2017
Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN study
Xavier Forns, Marina Berenguer, Kerstin Herzer, et al.
JHEP Reports : Innovation in Hepatology
|
December 30, 2025
Corrigendum to "Peginterferon-alpha-2a add-on to treatment with siRNA JNJ-73763989 in virologically suppressed chronic hepatitis B: The phase II PENGUIN study" [JHEP Reports 2025 7(10) 101516]
Edward Gane, Ewa Janczewska, Tetsuo Takehara, et al.
JHEP Reports : Innovation in Hepatology
|
September 8, 2025
Peginterferon-alpha-2a add-on to treatment with siRNA JNJ-73763989 in virologically suppressed chronic hepatitis B: The phase II PENGUIN study
Edward Gane, Ewa Janczewska, Tetsuo Takehara, et al.
Gut
|
January 25, 2023
Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection
Harry L A Janssen, Jinlin Hou, Tarik Asselah, et al.
Frontiers in Immunology
|
July 26, 2023
Plasma cells are not restricted to the CD27+ phenotype: characterization of CD27-CD43+ antibody-secreting cells
Kris Covens, Bert Verbinnen, Britt G de Jong, et al.
Antimicrobial Agents and Chemotherapy
|
February 24, 2010
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435
Oliver Lenz, Thierry Verbinnen, Tse-I Lin, et al.
The Lancet. Gastroenterology & Hepatology
|
July 13, 2023
Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial
Man-Fung Yuen, Tarik Asselah, Ira M Jacobson, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
June 19, 2026
No impact of low-dose nivolumab addition to JNJ-73763989 on HBsAg declines in chronic hepatitis B: the OCTOPUS-1 study
Tarik Asselah, Scott K Fung, Sila Akhan, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics
|
October 27, 2020
The broad phenotypic spectrum of PPP2R1A-related neurodevelopmental disorders correlates with the degree of biochemical dysfunction
Lisa Lenaerts, Sara Reynhout, Iris Verbinnen, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 91) with videos related to
Sort By:
Page
of 10
Journal of Gastroenterology and Hepatology
|
January 19, 2016
Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naïve patients in China and South Korea
Lai Wei, Tao Han, Dongliang Yang, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society
|
March 16, 2017
Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN study
Xavier Forns, Marina Berenguer, Kerstin Herzer, et al.
JHEP Reports : Innovation in Hepatology
|
December 30, 2025
Corrigendum to "Peginterferon-alpha-2a add-on to treatment with siRNA JNJ-73763989 in virologically suppressed chronic hepatitis B: The phase II PENGUIN study" [JHEP Reports 2025 7(10) 101516]
Edward Gane, Ewa Janczewska, Tetsuo Takehara, et al.
JHEP Reports : Innovation in Hepatology
|
September 8, 2025
Peginterferon-alpha-2a add-on to treatment with siRNA JNJ-73763989 in virologically suppressed chronic hepatitis B: The phase II PENGUIN study
Edward Gane, Ewa Janczewska, Tetsuo Takehara, et al.
Gut
|
January 25, 2023
Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection
Harry L A Janssen, Jinlin Hou, Tarik Asselah, et al.
Frontiers in Immunology
|
July 26, 2023
Plasma cells are not restricted to the CD27+ phenotype: characterization of CD27-CD43+ antibody-secreting cells
Kris Covens, Bert Verbinnen, Britt G de Jong, et al.
Antimicrobial Agents and Chemotherapy
|
February 24, 2010
In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435
Oliver Lenz, Thierry Verbinnen, Tse-I Lin, et al.
The Lancet. Gastroenterology & Hepatology
|
July 13, 2023
Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial
Man-Fung Yuen, Tarik Asselah, Ira M Jacobson, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
June 19, 2026
No impact of low-dose nivolumab addition to JNJ-73763989 on HBsAg declines in chronic hepatitis B: the OCTOPUS-1 study
Tarik Asselah, Scott K Fung, Sila Akhan, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics
|
October 27, 2020
The broad phenotypic spectrum of PPP2R1A-related neurodevelopmental disorders correlates with the degree of biochemical dysfunction
Lisa Lenaerts, Sara Reynhout, Iris Verbinnen, et al.
Page
of 10